Drug Delivery Innovations Driving Improved Patient Compliance

Aug 09, 2011, 04:53 ET from Reportlinker

NEW YORK, Aug. 9, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Drug Delivery Innovations Driving Improved Patient Compliance

http://www.reportlinker.com/p0591016/Drug-Delivery-Innovations-Driving-Improved-Patient-Compliance.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology

Introduction

This report gives in depth coverage of the factors driving patient non compliance. The report then goes on to describe and analyse key technologies being developed to improve compliance in the oral and parenteral delivery spaces. Finally the report looks at new delivery devices being developed which will improve patient compliance.

Features and benefits

* Understand the causes of poor patient compliance and the technologies that are already in use to overcome these causes.

* Assess key innovative modified release oral delivery technologies that are in development.

* Assess key innovative modified release parenteral technologies that are in development.

* Assess key innovative drug delivery devices that are in development and understand how they can improve patient compliance and for which indications.

Highlights

The importance of the oral route of administration from both a clinician and patient acceptance point of view means there has been a vast amount of development and research in drug delivery via this route. Noncompliance can be attributed to poor taste, difficulty in administration or swallowing, and the inconvenience of multiple doses per day.

Of all the modifications to parenteral delivery systems, the transdermal administration route is attracting the most attention. Across all parenteral delivery forms, the continued increase in the number of experimental protein and peptide drug candidates means that there is a high level of unmet need for delivery systems for these types of drugs.

Pharmaceutical devices will continue to drive patient compliance and acceptability as increased options make for a wider choice. The convergence of MEMS and nanotechnology with biological applications offers breakthrough in drug developments.

Your key questions answered

* What new technologies are being developed to improve patient compliance?

* Which companies are the leaders in the development of new delivery technologies aimed at improving compliance?

* What technologies in development can be applied to the specific therapy areas that my company is involved in?

* How will new technologies drive improvements in patient compliance?

* What new devices are in development that we could license to deliver our pipeline products?

Executive Summary

Overview and epidemiology of respiratory disorders

Global market analysis

Pipeline analysis

Competitive landscape

About the author

Disclaimer

Overview and epidemiology of respiratory disorders

Summary

Introduction

Asthma

Disease overview

Diagnosis, treatment and management

Epidemiology

Forecast epidemiology

COPD

Disease overview

Diagnosis, treatment and management

Epidemiology

Forecast epidemiology

Allergic rhinitis

Disease overview

Diagnosis, treatment and management

Epidemiology

Forecast epidemiology

Global market analysis

Summary

Introduction

Key events in the global respiratory market

New FDA recommendations state that LABAs cannot be used as monotherapy

FDA requires new outcomes studies for currently approved LABAs in asthma

FDA: inhalers that contain CFCs to be phased out in US

Merck's Dulera (formoterol/mometasone) approved by the FDA for asthma

Forest/Nycomed's Daxas approved in EU for severe COPD

SkyePharma's NDA for Flutiform rejected by FDA

Novartis's Xolair rejected by NICE for pediatric asthma

AstraZeneca launched Symbicort in Japan

GSK and Mitsubishi Tanabe ended Japanese tie-up for co-promotion of Adoair

Leading respiratory brands

Seretide

Singulair

Spiriva

Symbicort

Nasonex

Pulmicort

Flixotide

Combivent

Ventolin

Allegra

Market analysis by drug class

Drug class analysis

Asthma/COPD drugs

Allergic rhinitis drugs

Respiratory sales forecast to 2016

Pipeline analysis

Summary

Introduction

Key R&D events

GSK dropped darotropium from its COPD pipeline

Spiriva's safety review reveals that the drug was not associated with CV risk

Global respiratory pipeline

Leading drugs in development

Profiles of key pipeline products

Recently launched compounds

New drug application filed

Phase III compounds

Phase II compounds

Pipeline forecasts

Competitive landscape

Summary

Introduction

GSK

Merck & Co.

Boehringer Ingelheim

AstraZeneca

Novartis

Appendix

Scope

Methodology

Market size methodology

Epidemiology

Market forecast

References

Prevalence of asthma

Prevalence of COPD

Prevalence of allergic rhinitis

Abbreviations

To order this report:

Drug Delivery Technology Industry: Drug Delivery Innovations Driving Improved Patient Compliance

Drug Delivery Technology Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com